Peripheral blood mononuclear cells of chronic heart failure (CHF) patients produce great amounts of pro-inflammatory cytokines, indicating that circulating cells are activated and could mirror changes occurring in inflammatory cells infiltrating the failing heart. Adenosine is a regulatory metabolite acting through four membrane receptors that are linked to adenylyl cyclase: activation of the A 2A receptor subtype has been reported to inhibit cytokine release. Changes of the adenosinergic system may play a role in CHF development. Here we report an increase of A 2A receptor expression, density, and coupling to adenylyl cyclase in blood circulating cells of CHF patients. A 2A receptor up-regulation was also found in the explanted hearts of these patients, suggesting that changes of peripheral adenosine receptors mirror changes occurring in the disease target organ. In a cohort of patients followed longitudinally after heart transplantation, alterations of peripheral A 2A adenosine receptor progressively normalized to control values within 6 months, suggesting that improvement of cardiac performance is accompanied by progressive restoration of a normal adenosinergic system. These results validate the importance of the A 2A receptor in human diseases characterized by a marked inflammatory/immune component and suggest that the evaluation of this receptor in peripheral blood cells may be useful for monitoring hemodynamic changes and the efficacy of pharmacological and non-pharmacological treatments in CHF patients.
C hronic heart failure (CHF) is associated with reduced cardiac function resulting in inadequate tissue perfusion. Neurohumoral factors (1) and pro-inflammatory cytokines, including tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6) (2-5), play a pathogenic role in CHF and may contribute to progression of left ventricle dysfunction (LVD). These biological responses may act initially as compensatory mechanisms to improve cardiac function and peripheral perfusion and eventually become deleterious. For example, short-term expression of TNF-α within the heart is an adaptive response to biomechanical stress, whereas long-term expression may be maladaptive by producing cardiac decompensation (6) , LVD, cardiomyopathy, and the clinical manifestations of heart failure (7) . Peripheral blood mononuclear cells (PBMC) from CHF patients produce great amounts of TNF-α and IL-6 (2), indicating that circulating cells are activated and that they could mirror changes occurring in inflammatory cells, which infiltrate the failing myocardium. Adenosine is an important endogenous regulatory metabolite that acts through specific membrane receptors (the P1 receptors, encompassing the A 1 , A 2A , A 2B , and A 3 subtypes (8) . While A 1 and A 3 receptors inhibit adenylyl cyclase, the A 2A and A 2B subtypes stimulate this effector system and cAMP production (8) . Adenosine has important protective effects on the cardiovascular system. While stimulation of the A 1 and A 3 receptors in the heart has been associated to cardioprotection and ischemic preconditioning (9) , activation of the A 2A receptor subtype on coronary smooth muscle cells, endothelial cells, and monocytes/macrophages results in vasodilation (10) , neo-angiogenesis (11) , and inhibition of pro-inflammatory cytokines production (12) . Controversial results have been reported on the occurrence and function of this adenosine receptor in the heart (13, 14) . Several data highlight the importance of the adenosinergic system in CHF. Increased levels of adenosine in human plasma (15) and in the pericardial fluid in dogs (16) have been found to be associated with heart failure. Preliminary clinical data claim that the accumulation of endogenous adenosine by means of a drug, dipyridamole, which can prevent adenosine cellular uptake, significantly ameliorates hemodynamic changes in CHF patients (17) . On this basis and previous studies demonstrating that, in cardiovascular diseases, human circulating blood cells may express the same alterations occurring in the heart (18) , the present study has been designed to monitor adenosine plasma levels and the status of the A 2A receptor in the circulating cells of CHF patients and in the explanted hearts of patients undergoing cardiac transplantation. In particular, we specifically aimed at assessing: i) whether there are any changes of A 2A receptor parameters in the peripheral cells of CHF patients; ii) whether these changes mirror receptor changes occurring in the failing myocardium; and iii) whether changes of peripheral A 2A receptors normalize after heart transplantation.
MATERIALS AND METHODS

Subject demographics
A group of consecutive patients (40-33 men and 7 women-mean age 54.7 + 11.2 years) with end-stage heart failure were admitted to the institution for evaluation for cardiac transplantation and were enrolled for the study, according to the recommendations of the Declaration of Helsinki. The study protocol was approved by the local ethics committee of the Siena University, and the patients gave written informed consent. The cause of heart failure was coronary artery disease in 21 patients and idiopathic dilated cardiomyopathy in 19 patients. Of the patients, 31 were in New York Heart Association (NYHA) functional class III and 9 were in class IV; all patients had left ventricular ejection fraction <40%. All patients underwent right-side cardiac catheterization and hemodynamic findings, and medical treatments are reported in Table 1 .
Adenosine plasma levels
For adenosine determination, blood samples taken from CHF subjects and normal control volunteers anticoagulated with heparin (100 IU/ml of blood) were collected in ice-cooled syringes, containing a "stopping solution" (50 µM dipyridamole, Boehringer Ingelheim, Germany; 10 µM erythro-6-amino-9-(2-hydroxy-3-nonyl)-purine hydrochloride (EHNA), Wellcome Italia S.p.A., Pomezia, Italy; 79 µM α,β-methylene-adenosine-5'-diphosphate (AOPCP), Sigma Aldrich, Milan, Italy), in order to prevent cellular uptake, enzymatic deamination, or production from blood adenosine trisphosphate (ATP), respectively. The blood was centrifuged at 1800 g at 4°C, and then the plasma was immediately deproteinised with acetonitrile and the supernatant was analyzed for adenosine concentration by HPLC. The chromatographic method was performed in an isocratic system according to Shryock and coworkers (19) : the mobile phase consisted of 35 µM phosphate buffer, acetonitrile-methanol (90:5:5, v:v) at a flow rate 0.75 ml/min. The wavelength of detection was fixed at 254 nm.
Preparation of blood peripheral cell or membrane suspensions
Peripheral venous blood samples (50 ml) were obtained from CHF subjects and healthy controls. The isolation of the various cell fractions (lymphocytes, neutrophils) started no later than 6-8 h since drawing. Membranes from human lymphocytes and neutrophils were prepared as previously described (20) (21) (22) (23) and were used for radioligand binding assays. Lymphocytes and neutrophils were prepared as described previously (20) (21) (22) (23) and were used to mesure cAMP levels.
Preparation of cardiac membrane suspensions
Fresh material from explanted hearts was obtained immediately following surgery in the operation room. Four sections of left ventricular myocardium were taken: sample 1 from anterior wall, sample 2 from lateral wall, sample 3 from posterior wall, and finally sample 4 was taken as a transverse section, comprising the interventricular septum with the two right and left sides. Each sample comprised full-thickness epi-endocardium transversal sections. Myocardial specimens were immediately frozen in liquid nitrogen and stored at -80°C until the tests were performed. Control samples were obtained as reported above from postmortem hearts of control individuals. The cardiac tissues were homogenized and filtered through two layers of gauze. The homogenate was centrifuged and the pellet was resuspended in a buffer containing 2 IU/ml adenosine deaminase and was incubated for 30 min at 37°C. The suspension was centrifuged again, and the final pellet was resuspended and used for radioligand binding assays (24) . H]-ZM 241385 in the 0.01-10 nM range at 4°C for 60 min. Non-specific binding was determined in the presence of 1 µM ZM 241385. Bound and free radioactivity were separated by filtering the assay mixture through Whatman GF/C glass fiber filters by use of a Brandel cell harvester. The filter-bound radioactivity was counted by using a Beckman liquid scintillation counter with an efficiency of 55%. Saturation binding experiments were also performed as described above by incubating cardiac membrane suspensions from explanted hearts of CHF subjects and from postmortem hearts of control individuals.
Measurement of cyclic AMP levels in human lymphocytes or neutrophils
Adenylyl cyclase activity was evaluated by incubating blood peripheral cells (lymphocytes, neutrophils) in the absence or in the presence of 6-8 different concentrations of the A 2A adenosine agonist NECA (N-ethylcarboxamidoadenosine). Cells were suspended in 0.5 ml of incubation buffer containing 2 IU of adenosine deaminase and 0.5 mM of 4-3-butoxy-4-methoxybenzyl-2-imidazolidinone (Ro 20-1724) as phosphodieterase inhibitor and were preincubated in a shaking bath at 37°C. Then NECA was added to the mixture and the incubation continued for another 10 min. The reaction was terminated by the addition of cold 6% trichloroacetic acid (TCA). Samples were centrifuged, and the final aqueous solution tested for cAMP levels by a competition protein-binding assay as previously described (22) .
RT-PCR
Blood has been collected aseptically and PBMC was separated immediately by centrifugation on Lymphoprep gradient, washed, and resuspended in Trizol reagent for RNA extraction. Retrotrascription of RNA has been performed with MuLV Retrotrascriptase (APPLERA), and the level of A 2A receptor expression has been evaluated by semiquantitative reverse transciptase polymerase chain reaction (RT-PCR) analysis by using 32 PdCTP to label the amplification products. The cDNAs have been amplified by using specific primers for the human A 2A receptor: (A 2A FW: 5'-TGTCCTGGTCCTCACGCAGAG-3'; A 2A Rev: 5'-CGGATCCTGTAGGCGTAGATGAAGG-3'). PCR assays have been performed for 34 and 38 cycles with the following parameters: denaturation at 95°C for 60 s, annealing at 55°C for 60 s, extension at 72°C for 60 s. Amplified products have been separated on 6% polyacrylamide-TrisBorate-EDTA gels followed by gel drying and autoradiography. For each patient, semiquantitative analysis of amplified PCR products has been performed by densitometric analysis of autoradiograms by Quantity One software and was normalized to the corresponding beta actin product. In all cases, data have been compared with age-matched controls.
Statistical analysis
A weighted nonlinear least-squares curve-fitting program, LIGAND (27) , was used for computer analysis of the data from the saturation experiments. EC 50 values in the cAMP assay were calculated with the non-linear least-squares curve-fitting program Prism (Graph PAD, San Diego, CA). Analysis of data for both binding and cAMP experiments was done by one-way ANOVA. Analysis of difference between control and CHF subjects was done with Student's ttest (unpaired analysis). Differences were considered significant at a value of P<0.01. All data are reported as mean ± SEM.
RESULTS
Plasma adenosine levels in CHF patients
In CHF patients (n=39), plasma adenosine concentrations (310.5±42.1 nmol/L) were significantly higher (P<0.01) with respect to control subjects (216.7±25.7 nmol/L; n=32). In four patients undergoing cardiac transplantation, adenosine plasma levels progressively decreased during the first six months after operation, although they did not reach the normal range within this period. Basal values before and six months after transplantation changed as follows: case 1, from 305 to 297 nmol/L; case 2, from 312 to 281 nmol/L; case 3, from 360 to 287 nmol/L; case 4, from 321 to 289 nmol/L. In agreement with previous literature data (5), these patients also showed increased TNF-α and IL-6 plasma levels (data not shown).
Up-regulation of the adenosine A 2A receptor and transduction system in CHF patients
In CHF patients, the A 2A ligand [ 3 H]-ZM 241385 bound to lymphocyte (A) and neutrophil (B) membranes with significantly increased K D and Bmax values with respect to control subjects (P<0.01) (Fig. 1, Table 2 ). RT-PCR analysis in the PBMC of CHF subjects revealed a significant increase of A 2A receptor expression compared with control subjects (Fig. 2) . In CHF explanted hearts, [ 3 H]-ZM 241385 binding parameters showed alterations (Fig. 3 ) comparable with those observed in the corresponding blood peripheral cells (Fig. 1) , suggesting that the latter may reproduce the changes occurring in the disease target organ. [ 3 H]-ZM 241385 binding in fragments (see Materials and Methods) of four different ventricular regions of the hearts of CHF or postmortem control individuals showed no differences of A 2A receptor parameters (data not shown). Also in the heart, increased A 2A receptor density is likely due to increased receptor expression, as suggested by preliminary RT-PCR data obtained in myocardial samples of these same subjects (data not shown). As shown in Figures 1 and 3 , an increase of K D values was also detected in the peripheral cells and myocardium of CHF patients with respect to controls, suggesting a decrease of ligand binding affinity. To assess how these changes of binding parameters can affect A 2A receptor function, we measured the ability of the A 2A agonist NECA to stimulate cAMP accumulation in both lymphocytes (Fig. 4A) and neutrophils (Fig. 4B) . In CHF patients, agonist concentration-response curves were significantly shifted to the left with respect to control subjects, indicating an increased potency of NECA to stimulate cAMP formation (P<0.01). Consistently, NECA EC 50 values (i.e., the agonist concentrations producing halfmaximal effect) were significantly lower in the cells of CHF subjects with respect to controls (Fig. 4) .
Normalization of A 2A adenosine receptor parameters after heart transplantation
In a cohort of CHF patients, the peripheral A 2A receptor has been studied longitudinally as a function of time before and after transplantation. Table 3 shows the values of A 2A receptor binding (K D and Bmax) in lymphocyte membranes of six subjects before heart transplantation (pre-transplantation values) and 2-4, 4-8, 8-12, and 12-24 weeks after transplant. Consistent with results reported in Table 2 , binding values were significantly increased before transplantation with respect to control subjects. After transplant, both K D and Bmax gradually and progressively decreased to control values within 12-24 weeks (Table 3 ). This trend was consistently evident for all evaluated patients and was also detected in the neutrophils of the same subjects, showing a progressive normalization of binding parameters to control values as a function of time (Fig. 5) . In the PBMC of four patients (subjects 2, 4, 5, and 6), longitudinal RT-PCR analysis revealed a marked and time-dependent decrease of A 2A receptor mRNA (Table 3) . Consistent with this data, in one additional patient monitored 24 weeks after transplant, A 2A receptor expression was reduced to 33% of corresponding pre-transplantation level; moreover, in 19 patients analyzed at one single time point around 12 months after transplant in comparison with 26 control subjects, adenosine A 2A receptor mRNA was still 44+8% of control values (P<0.05).
In parallel with the decrease of plasma adenosine concentrations (see above), in these same patients TNF-α and IL-6 plasma levels also showed a trend to a decrease to control values within 3-6 months after transplant (data not shown). 3 H]-ZM 241385 K D value was also found in cells from CHF patients with respect to controls. The potency of the adenosine analog NECA to stimulate adenylyl cyclase (the transduction system typically associated to the A 2A receptor) was significantly increased in CHF patients. This finding is in line with the hypothesized ratio of G-protein-coupled receptors and transductional G-proteins in cell membranes (29) : Increased receptor number is expected to result in increased coupling to G-proteins, which in turn results in an increase of the functional response. On this basis, we conclude that altered coupling of increased A 2A receptors to transductional proteins contribute to the amplification of adenylyl cyclase response in CHF subjects. Similar findings were observed in the explanted hearts of CHF patients, where [ 3 H]-ZM 241385 K D and Bmax values were significantly higher comapred with control hearts. Our data also confirm previous reports on the occurrence of A 2A adenosine receptors in human ventricular homogenates (30) . Because the study has been performed in homogenates of whole heart, we cannot exclude that other cell types (e.g., endothelial cells, fibroblasts, infiltrating inflammatory cells) might also contribute to this result. However, cardiomyocytes are by far the most abundant cell in the myocardium and the very similar binding data observed in different regions of the ventricle wall (data not shown), in which different contribution of other cell types could occur, seem to confirm a predominant role for ventricular myocytes. Globally, these results suggest that i) A 2A receptors are expressed in human myocardium; and ii) these receptors are up-regulated in both myocardium and circulating cells of CHF patients. We speculate that, in the myocardium, upregulation of A 2A receptors may represent a compensatory response to preserve contractility. In this respect, conflicting results have been reported regarding the effects of A 2A receptor agonists on myocardial contractility, with both no effect (13, 31) and induction of positive inotropic effects (32) (33) (34) . Therefore, when we propose that A 2A receptor up-regulation may help preserve heart contractility, we also speculate on the counter-regulatory effect of A 2A receptor activation on the synthesis of TNF-α,  which is provided with direct negative inotropic effect (4). We also conclude that, in CHF, peripheral blood circulating cells express receptor changes that closely mirror the changes occurring in the disease target organ.
A concomitant modest increase of adenosine plasma levels (likely due to myocardial ischemia and sympathetic activation) was also registered in CHF patients, in agreement with previous data (15, 16) . Although adenosine receptors have been described to undergo desensitization when overexposed to agonists for long periods (35) , our data showing up-regulation of A 2A receptor density and expression in CHF subjects suggest that the modest adenosine increase observed in these patients cannot provoke desensitization of either the receptor itself or its G protein.
A second important finding of the present study is the observation that the up-regulation of A 2A receptors in circulating blood cells progressively normalizes after cardiac transplantation. Six months after the operation, in both lymphocytes and neutrophils of six patients, control values of A 2A receptor Bmax and K D were found, with levels of A 2A receptor mRNA even lower in four (out of six patients) with respect to control subjects. Such a reduction could be the consequence of a low transcription rate required to normalize A 2A receptor density. Plasma adenosine levels also showed a trend to a decrease to values within the normal range. Hence, the improvement of cardiac performance (and likely of the neurohumoral milieu) after transplantation is associated with a progressive restoration of a normal adenosinergic system, at least in terms of A 2A receptor expression and activity.
Further studies are needed to fully clarify the time-course of adenosinergic system changes in the early phase and during the progression of heart failure. This finding will add information on the pathophysiology of cardiac insufficiency and possible suggestions for novel pharmacological treatments. As underlined above, adenosine has potent cardioprotective actions (9) , which are, at least in part, mediated by modulation of the release and actions of pro-inflammatory cytokines. Specifically, via activation of A 2A receptors, adenosine decreases LPS-stimulated macrophage TNF-α and IL-6 production (12), attenuates the expression of TNF-α in the failing human heart, decreases ischemia-induced cardiac TNF-α formation (12, 36) , and prevents TNF-α-dependent myocardial dysfunction in experimental animals (36) . The possible relevance of this anticytokine effect to human CHF is confirmed by recent studies demonstrating that the failing human heart re-expresses TNF-α  and that there is a direct relationship between the severity of disease and plasma TNF-α levels (2, 5) . Therefore, an increased production of endogenous adenosine and/or an increased expression and activity of adenosine receptors could be compensatory against CHF. An attractive, although indirect, support to the hypothesis of a protective role for endogenous adenosine in CHF has been recently provided (37) . Patients with a relatively common mutation in at least one allele of the adenosine monophosphate deaminase 1 gene (leading to increased adenosine production), experienced a significantly longer duration of heart failure symptoms before referral for transplantation evaluation and had a greater chance of surviving without a cardiac transplant than patients homozygous for the wild-type allele. Regarding the mechanisms at the basis of CHF-associated A 2A receptor up-regulation, previous data suggest that the expression and function of adenosine receptors is regulated by several endogenous inflammatory factors, including cytokines themselves. For example, Xaus et al. (38) reported that interferon (IFN)-γ  regulates expression of A 2B receptors and promotes macrophage activation. In a recent paper, Khoa and co-workers (39) demonstrated that inflammatory cytokines (IL-1 and TNF-α) increase both the expression and the protein level of A 2A receptors in a human monocytic cell line. In the same model, there was an elevated cAMP production after treatment with an A 2A receptor agonist (CGS-21680) in IL-1 and TNF-α-treated monocytes. Therefore, the cytokine milieu may regulate the function and the expression of A 2A adenosine receptors, and we speculate that by doing so, it may contribute to establishing negative feedback mechanisms against the progressive loop between pro-inflammatory cytokines and heart failure. On this basis, in future studies we will specifically investigate whether TNF-α (as well as other cytokines) can affect the transcription of the A 2A receptor gene and/or influence the stability of its mRNA. This will allow us to establish which of these two parameters (i.e., the A 2A receptor or TNF-α) could represent a better predictor of heart failure. Changes in expression of another Gprotein coupled receptor (i.e., the beta 2 -adrenoceptor) have been demonstrated in the peripheral blood mononuclear cells of CHF patients (40) . This effect was associated with functional uncoupling of the receptor from its intracellular signal transduction pathway. However, at present there are no data available on the longitudinal changes of this receptor before and after heart transplantation.
As shown in Table 1 , CHF patients were on treatment with several different drugs. Although no evidence exists that any of these drugs can affect the adenosinergic system, we cannot completely rule out such a possibility. Similarly, transplanted patients were treated with immunosuppressive drugs (azathioprine, corticosteroids and cyclosporin A). Recently, calcineurin inhibitors (cyclosporin A and Tacrolimus) have been shown to increase plasma adenosine concentrations (41) . It is possible that this effect could counteract the reduction of plasma adenosine upon cardiac transplantation and hemodynamic restoration. On the other hand, no evidence exists of any possible effects of calcineurin inhibitors on adenosine receptor expression and function, as also indirectly confirmed by our data showing a normalization of A 2A receptor binding parameters within 6 months after transplant. Globally, the present data suggest that the peripheral circulating cells of CHF patients express the same changes of the A 2A adenosine receptor occurring in the failing heart. Upon heart transplantation, peripheral A 2A receptor parameters gradually normalize in parallel with the normalization of hemodynamic parameters. Hence, the evaluation of the expression and function of these receptors in peripheral blood cells may be useful for monitoring hemodynamic changes and the efficacy of pharmacological and non-pharmacological treatments in CHF patients. 6 in neutrophils and lymphocytes, respectively. Corresponding maximal cyclic AMP levels (i.e., values obtained in the presence of 10 µM NECA) were 114±12 and 92±10 pmoles/10 6 in neutrophils and lymphocytes, respectively. In CHF subjects, basal cAMP levels were: 23±3 and 19±3 pmoles/10 6 in neutrophils and lymphocytes, respectively. Corresponding maximal cyclic AMP levels (in the presence of 10 µM NECA) were 120±15 and 98±11 pmoles/10 6 in neutrophils and lymphocytes, respectively. Data are the mean of different individual experiments. In CHF subjects, NECA EC 50 value (i.e., the agonist concentrations producing half-maximal effect) was significantly lower with respect to control subjects (*P<0.01, one-way ANOVA followed by Student's t-test). of subjects 1= , 2=5, 3=6, 4= at various times after transplant (from 2-4 to 12-24 weeks after transplantation) compared with pre-transplantation values (CHF) and control subjects (healthy controls, n=20). Affinity (K D ) values are reported in (B and D) ; Bmax values are reported in (A and C). CHF, chronic heart failure; A.T., after transplantation.
